Susan J. Coker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Susan J. Coker has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
G Michael
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
2 shared publicationsJ Dempster
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde Glasgow, UK
2 shared publicationsK A Kane
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde Glasgow, UK
2 shared publications- András Farkas
2nd Department of Internal Medicine and Cardiology Centre, University of Szeged, Szeged, Hungary
1 shared publication G Hart
Division of Clinical Science, The University of Liverpool UK
1 shared publicationGeorge Hart
Division of Clinical Science, The University of Liverpool, Liverpool, L69 3BX, UK
1 shared publication
Latest Publications
- 1 August 2008
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 119 (2) , 186-194
Drugs for men and women — How important is gender as a risk factor for TdP?
- 1 August 2008
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 119 (2) , 186-194
Drugs for men and women — How important is gender as a risk factor for TdP?
- 1 August 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (7) , 1414-1426
Adrenaline reveals the torsadogenic effect of combined blockade of potassium channels in anaesthetized guinea pigs
Background and purpose: Torsade de pointes (TdP) can be induced in several species by a reduction in cardiac repolarizing capacity. The aim of this study was to assess whether combinedIKrandIKsblockade could induce TdP in anaesthetized guinea pigs and whether short‐term variability (STV) or triangulation of action potentials could predict TdP.Experimental approach: Experiments were performed in open‐chest, pentobarbital‐anaesthetized, adrenaline‐stimulated male Dunkin Hartley guinea pigs, which received three consecutive i.v. infusions of either vehicle, theIKrblocker E‐4031 (3, 10 and 30 nmol kg−1 min−1), theIKsblocker HMR1556 (75, 250, 750 nmol kg−1 min−1) or E‐4031 and HMR1556 combined. Phenylephrine‐stimulated guinea pigs were also treated with the K+channel blockers in combination. Arterial blood pressure, ECGs and epicardial monophasic action potential (MAP) were recorded.Key results: TdP was observed in 75% of adrenaline‐stimulated guinea pigs given the K+channel blockers in combination, but was not observed in guinea pigs treated with eitherIKblocker alone, or in phenylephrine‐stimulated guinea pigs. Salvos and ventricular tachycardia occurred with adrenaline but not with phenylephrine. No changes in STV or triangulation of the MAP signals were observed before TdP.Conclusions and implications: Combined blockade of bothIKrandIKsplus the addition of adrenaline were required to induce TdP in anaesthetized guinea pigs. This suggests that there must be sufficient depletion of repolarization reserve and an appropriate trigger for TdP to occur.British Journal of Pharmacology(2008)154, 1414–1426; doi:10.1038/bjp.2008.169; published online 19 May 2008
- 1 August 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (7) , 1414-1426
Adrenaline reveals the torsadogenic effect of combined blockade of potassium channels in anaesthetized guinea pigs
Background and purpose: Torsade de pointes (TdP) can be induced in several species by a reduction in cardiac repolarizing capacity. The aim of this study was to assess whether combinedIKrandIKsblockade could induce TdP in anaesthetized guinea pigs and whether short‐term variability (STV) or triangulation of action potentials could predict TdP.Experimental approach: Experiments were performed in open‐chest, pentobarbital‐anaesthetized, adrenaline‐stimulated male Dunkin Hartley guinea pigs, which received three consecutive i.v. infusions of either vehicle, theIKrblocker E‐4031 (3, 10 and 30 nmol kg−1 min−1), theIKsblocker HMR1556 (75, 250, 750 nmol kg−1 min−1) or E‐4031 and HMR1556 combined. Phenylephrine‐stimulated guinea pigs were also treated with the K+channel blockers in combination. Arterial blood pressure, ECGs and epicardial monophasic action potential (MAP) were recorded.Key results: TdP was observed in 75% of adrenaline‐stimulated guinea pigs given the K+channel blockers in combination, but was not observed in guinea pigs treated with eitherIKblocker alone, or in phenylephrine‐stimulated guinea pigs. Salvos and ventricular tachycardia occurred with adrenaline but not with phenylephrine. No changes in STV or triangulation of the MAP signals were observed before TdP.Conclusions and implications: Combined blockade of bothIKrandIKsplus the addition of adrenaline were required to induce TdP in anaesthetized guinea pigs. This suggests that there must be sufficient depletion of repolarization reserve and an appropriate trigger for TdP to occur.British Journal of Pharmacology(2008)154, 1414–1426; doi:10.1038/bjp.2008.169; published online 19 May 2008
- Open Access
- 1 July 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (5) , 958-970
Importance of vagally mediated bradycardia for the induction of torsade de pointes in an in vivo model
Background and purpose: Bradycardia is a risk factor for the development of torsade de pointes (TdP). The aim of this work was to compare the importance of changes in heart rate and arterial blood pressure in the development of drug‐induced TdP and to investigate the role of vagal influences.Experimental approach: Experiments were performed in open‐chest, pentobarbital‐anaesthetized, male rabbits which were given clofilium (20, 60 and 200 nmol kg−1 min−1) with rising doses of either phenylephrine (75, 150, 225 and 300 nmol kg−1 min−1), angiotensin II (0.25, 0.5, 0.75 and 1 nmol kg−1 min−1) or saline. A fourth group received phenylephrine and cloflium after bilateral vagotomy. ECGs, haemodynamics and epicardial monophasic action potentials were recorded.Key results: TdP occurred in 57% of rabbits given phenylephrine and clofilium. Replacement of phenylephrine with saline or angiotensin II reduced the incidence of TdP to 0 and 17%, respectively. Vagotomy prevented TdP in rabbits given phenylephrine and clofilium. Increases in blood pressure induced by phenylephrine and angiotensin II were similar. Bradycardia only occurred with phenylephrine and was reduced but not abolished by vagotomy. Neither short‐term variability of repolarization nor action potential triangulation could predict TdP.Conclusions and implications: These results indicate that reflex activation of vagal nerve activity is essential for the induction of drug‐induced TdP in α1‐adrenoceptor‐stimulated anaesthetized rabbits. This implies that alterations in vagal activity may also precipitate episodes of drug‐induced TdP in man and that this should be considered in selecting models used in drug development.British Journal of Pharmacology (2008) 154, 958–970; doi:10.1038/bjp.2008.154; published online 21 April 2008
- 1 July 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (5) , 958-970
Open AccessImportance of vagally mediated bradycardia for the induction of torsade de pointes in an in vivo model
Background and purpose: Bradycardia is a risk factor for the development of torsade de pointes (TdP). The aim of this work was to compare the importance of changes in heart rate and arterial blood pressure in the development of drug‐induced TdP and to investigate the role of vagal influences.Experimental approach: Experiments were performed in open‐chest, pentobarbital‐anaesthetized, male rabbits which were given clofilium (20, 60 and 200 nmol kg−1 min−1) with rising doses of either phenylephrine (75, 150, 225 and 300 nmol kg−1 min−1), angiotensin II (0.25, 0.5, 0.75 and 1 nmol kg−1 min−1) or saline. A fourth group received phenylephrine and cloflium after bilateral vagotomy. ECGs, haemodynamics and epicardial monophasic action potentials were recorded.Key results: TdP occurred in 57% of rabbits given phenylephrine and clofilium. Replacement of phenylephrine with saline or angiotensin II reduced the incidence of TdP to 0 and 17%, respectively. Vagotomy prevented TdP in rabbits given phenylephrine and clofilium. Increases in blood pressure induced by phenylephrine and angiotensin II were similar. Bradycardia only occurred with phenylephrine and was reduced but not abolished by vagotomy. Neither short‐term variability of repolarization nor action potential triangulation could predict TdP.Conclusions and implications: These results indicate that reflex activation of vagal nerve activity is essential for the induction of drug‐induced TdP in α1‐adrenoceptor‐stimulated anaesthetized rabbits. This implies that alterations in vagal activity may also precipitate episodes of drug‐induced TdP in man and that this should be considered in selecting models used in drug development.British Journal of Pharmacology (2008) 154, 958–970; doi:10.1038/bjp.2008.154; published online 21 April 2008
- 1 December 2007
- Published by Wiley in British Journal of Pharmacology
- Vol. 152 (8) , 1215-1227
Potentiation of E‐4031‐induced torsade de pointes by HMR1556 or ATX‐II is not predicted by action potential short‐term variability or triangulation
Background and purpose: Torsade de pointes (TdP) can be induced by a reduction in cardiac repolarizing capacity. The aim of this study was to assess whether I Ks blockade or enhancement of I Na could potentiate TdP induced by I Kr blockade and to investigate whether short‐term variability (STV) or triangulation of action potentials preceded TdP.Experimental approach: Experiments were performed in open‐chest, pentobarbital‐anaesthetized, α1‐adrenoceptor‐stimulated, male New Zealand White rabbits, which received three consecutive i.v. infusions of either the I Kr blocker E‐4031 (1, 3 and 10 nmol kg−1 min−1), the I Ks blocker HMR1556 (25, 75 and 250 nmol kg−1 min−1) or E‐4031 and HMR1556 combined. In a second study rabbits received either the same doses of E‐4031, the I Na enhancer, ATX‐II (0.4, 1.2 and 4.0 nmol kg−1) or both of these drugs. ECGs and epicardial monophasic action potentials were recorded.Key results: HMR1556 alone did not cause TdP but increased E‐4031‐induced TdP from 25 to 80%. ATX‐II alone caused TdP in 38% of rabbits, as did E‐4031; 75% of rabbits receiving both drugs had TdP. QT intervals were prolonged by all drugs but the extent of QT prolongation was not related to the occurrence of TdP. No changes in STV were detected and triangulation was only increased after TdP occurred.Conclusions and implications: Giving modulators of ion channels in combination substantially increased TdP but, in this model, neither STV nor triangulation of action potentials could predict TdP.British Journal of Pharmacology (2007) 152, 1215–1227; doi:10.1038/sj.bjp.0707513; published online 29 October 2007
- 1 December 2007
- Published by Wiley in British Journal of Pharmacology
- Vol. 152 (8) , 1215-1227
Potentiation of E‐4031‐induced torsade de pointes by HMR1556 or ATX‐II is not predicted by action potential short‐term variability or triangulation
Background and purpose: Torsade de pointes (TdP) can be induced by a reduction in cardiac repolarizing capacity. The aim of this study was to assess whether I Ks blockade or enhancement of I Na could potentiate TdP induced by I Kr blockade and to investigate whether short‐term variability (STV) or triangulation of action potentials preceded TdP.Experimental approach: Experiments were performed in open‐chest, pentobarbital‐anaesthetized, α1‐adrenoceptor‐stimulated, male New Zealand White rabbits, which received three consecutive i.v. infusions of either the I Kr blocker E‐4031 (1, 3 and 10 nmol kg−1 min−1), the I Ks blocker HMR1556 (25, 75 and 250 nmol kg−1 min−1) or E‐4031 and HMR1556 combined. In a second study rabbits received either the same doses of E‐4031, the I Na enhancer, ATX‐II (0.4, 1.2 and 4.0 nmol kg−1) or both of these drugs. ECGs and epicardial monophasic action potentials were recorded.Key results: HMR1556 alone did not cause TdP but increased E‐4031‐induced TdP from 25 to 80%. ATX‐II alone caused TdP in 38% of rabbits, as did E‐4031; 75% of rabbits receiving both drugs had TdP. QT intervals were prolonged by all drugs but the extent of QT prolongation was not related to the occurrence of TdP. No changes in STV were detected and triangulation was only increased after TdP occurred.Conclusions and implications: Giving modulators of ion channels in combination substantially increased TdP but, in this model, neither STV nor triangulation of action potentials could predict TdP.British Journal of Pharmacology (2007) 152, 1215–1227; doi:10.1038/sj.bjp.0707513; published online 29 October 2007
- 26 July 2007
- Published by Elsevier in European Journal of Pharmacology
- Vol. 575 (1-3) , 113-121
A gender-independent proarrhythmic action of 17β-estradiol in anaesthetized rabbits
- 26 July 2007
- Published by Elsevier in European Journal of Pharmacology
- Vol. 575 (1-3) , 113-121
A gender-independent proarrhythmic action of 17β-estradiol in anaesthetized rabbits
- Open Access
- 1 October 2006
- Published by Wiley in British Journal of Pharmacology
- Vol. 149 (3) , 233-242
Greater antiarrhythmic activity of acute 17β‐estradiol in female than male anaesthetized rats: correlation with Ca2+ channel blockade
Background and purpose: Female sex hormones may protect pre‐menopausal women from sudden cardiac death. We therefore investigated the effects of the main female sex hormone, 17β‐estradiol, on ischaemia‐induced cardiac arrhythmias and on the L‐type Ca2+ current (ICaL).Experimental approach: In vivo experiments were performed in pentobarbital‐anaesthetized rats subjected to acute coronary artery occlusion. ICaL was measured by the whole‐cell patch‐clamp technique, in rat isolated ventricular myocytes.Key results: Acute intravenous administration of 17β‐estradiol as a bolus dose followed by a continuous infusion, commencing 10 min before coronary artery occlusion, had dose‐dependent antiarrhythmic activity. In female rats 300 ng kg‐1 + 30 ng kg−1 min−1 17β‐estradiol significantly reduced the number of ventricular premature beats (VPBs) and the incidence of ventricular fibrillation (VF). A ten fold higher dose of 17β‐estradiol was required to cause similar effects in male rats. In vitro 17β‐estradiol reduced peak ICaL in a concentration‐dependent manner. The EC50 was ten‐fold higher in male myocytes (0.66 μM) than in females (0.06 μM).Conclusions and implications: These results indicate that 17β‐estradiol has marked dose‐dependent antiarrhythmic activity that is greater in female rats than in males. A similar differential potency in blocking ICaL in myocytes from female and male rats can account for this effect. This provides an explanation for the antiarrhythmic activity of 17β‐estradiol and gender‐selective protection against sudden cardiac death.British Journal of Pharmacology (2006) 149, 233–242. doi:10.1038/sj.bjp.0706850
- 1 October 2006
- Published by Wiley in British Journal of Pharmacology
- Vol. 149 (3) , 233-242
Open AccessGreater antiarrhythmic activity of acute 17β‐estradiol in female than male anaesthetized rats: correlation with Ca2+ channel blockade
Background and purpose: Female sex hormones may protect pre‐menopausal women from sudden cardiac death. We therefore investigated the effects of the main female sex hormone, 17β‐estradiol, on ischaemia‐induced cardiac arrhythmias and on the L‐type Ca2+ current (ICaL).Experimental approach: In vivo experiments were performed in pentobarbital‐anaesthetized rats subjected to acute coronary artery occlusion. ICaL was measured by the whole‐cell patch‐clamp technique, in rat isolated ventricular myocytes.Key results: Acute intravenous administration of 17β‐estradiol as a bolus dose followed by a continuous infusion, commencing 10 min before coronary artery occlusion, had dose‐dependent antiarrhythmic activity. In female rats 300 ng kg‐1 + 30 ng kg−1 min−1 17β‐estradiol significantly reduced the number of ventricular premature beats (VPBs) and the incidence of ventricular fibrillation (VF). A ten fold higher dose of 17β‐estradiol was required to cause similar effects in male rats. In vitro 17β‐estradiol reduced peak ICaL in a concentration‐dependent manner. The EC50 was ten‐fold higher in male myocytes (0.66 μM) than in females (0.06 μM).Conclusions and implications: These results indicate that 17β‐estradiol has marked dose‐dependent antiarrhythmic activity that is greater in female rats than in males. A similar differential potency in blocking ICaL in myocytes from female and male rats can account for this effect. This provides an explanation for the antiarrhythmic activity of 17β‐estradiol and gender‐selective protection against sudden cardiac death.British Journal of Pharmacology (2006) 149, 233–242. doi:10.1038/sj.bjp.0706850